9.765

2.36% 0.225

Igm Biosciences Inc (IGMS)

Overview News Price History Option Chain Financials Discussions Forecast

Igm Biosciences Inc stock is traded at $9.765, with a volume of 197.43K. It is up +2.36% in the last 24 hours and down -41.60% over the past month. IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Previous Close:

$9.54

Open:

$9.35

24h Volume:

197.43K

Relative Volume:

0.67

Market Cap:

$580.67M

Revenue:

$2.91M

Net Income/Loss:

$-220.40M

P/E Ratio:

-1.8529

EPS:

-5.27

Net Cash Flow:

$-176.15M

1W Performance:

-12.42%

1M Performance:

-41.60%

6M Performance:

+16.67%

1Y Performance:

+63.29%

1-Day Range:

$9.23

$10.08

1-Week Range:

$8.58

$11.32

52-Week Range:

$4.72

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Name

Igm Biosciences Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

650-965-7873

Address

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Employee

198

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

IGMS's Discussions on Twitter

Compare IGMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IGMS	9.765	580.67M	2.91M	-220.40M	-176.15M	-5.27
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-22	Resumed	Jefferies	Buy
Oct-17-22	Initiated	JP Morgan	Neutral
Aug-29-22	Initiated	BofA Securities	Buy
Dec-13-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-21	Upgrade	Wedbush	Neutral → Outperform
Aug-26-21	Initiated	Morgan Stanley	Overweight
Jan-29-21	Initiated	RBC Capital Mkts	Outperform
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Dec-22-20	Downgrade	Wedbush	Outperform → Neutral
Jul-17-20	Initiated	Robert W. Baird	Outperform
Jul-01-20	Initiated	H.C. Wainwright	Buy
May-28-20	Initiated	SunTrust	Buy
Apr-22-20	Initiated	Wedbush	Outperform
Oct-14-19	Initiated	Guggenheim	Buy
Oct-14-19	Initiated	Jefferies	Buy
Oct-14-19	Initiated	Piper Jaffray	Overweight
Oct-14-19	Initiated	Stifel	Buy

View All

Igm Biosciences Inc Stock (IGMS) Latest News

Nov 20, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Nov 20, 2024

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Nov 20, 2024

Nov 15, 2024

Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews

Nov 15, 2024

Nov 13, 2024

IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com

Nov 13, 2024

Biotech firm backs off its focus on oncology research - Silicon Valley Business Journal

Nov 11, 2024

IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat

Nov 11, 2024

Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN

Nov 11, 2024

Nov 10, 2024

IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 10, 2024

Nov 09, 2024

IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat

Nov 09, 2024

Nov 08, 2024